Biodesix Raises $7.1M in Series C Financing Round

The funding will go toward ongoing commercialization efforts for VeriStrat, the company's protein biomarker-based companion diagnostic for non-small cell lung cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.